Shift Bioscience
Brendan Swain, PhD, is currently serving as the Chief Scientific Officer at Shift Bioscience, a position held since March 2021. Prior to this role, Brendan completed a Doctor of Philosophy in Pharmacology at the University of Cambridge from 2016 to 2020, following an undergraduate degree in Natural Sciences with a focus on Pharmacology at the same institution from 2013 to 2016. Brendan's academic journey began at Dame Alice Owen's School, where studies were completed from 2006 to 2013.
This person is not in any teams
Shift Bioscience
Shift Bioscience is unlocking safe rejuvenation with cell simulations. Cellular reprogramming is a powerful biological pathway that can reverse ageing and age-driven diseases in the dish but is not yet safe for clinical use. Our team based in Cambridge UK has pioneered the first high throughput, high accuracy ageing biomarker, which can be leveraged in AI-based cell simulations to identify drug targets for safe rejuvenation.